Nevada Attorney General Aaron Ford joined 43 states and territories Monday in a $400 million settlement in principle with Sandoz Inc. The agreement targets allegations that the generic-drug maker conspired to inflate prices and limit competition across numerous prescription medications.
The Nevada AG’s office said the deal reflects years of work by attorneys and investigators nationwide. Ford said pharmaceutical companies that manipulate prices and restrict competition ultimately make consumers pay the price, but the announcement did not identify Nevada’s expected share or announce a claim process.
A Long-Running Generic-Drug Fight
The Sandoz agreement is the latest turn in a multistate antitrust campaign that has been building for years. In February, the Wisconsin Department of Justice said 42 states and territories had filed a new complaint against Novartis AG and Sandoz Group AG subsidiaries, alleging a coordinated effort to fix prices, allocate markets and rig bids for 31 generic drugs.
That complaint also alleged Novartis moved assets and spun off Sandoz Inc. in a way intended to shield the parent company from liability in earlier litigation. The broader state cases draw on more than 20 million documents and millions of phone records involving hundreds of generic-drug sales and pricing executives, according to the Wisconsin filing.
Nevada Has Already Seen One Settlement
Ford’s announcement follows a separate $29.6 million Glenmark settlement announced in July over allegations involving more than 100 generic prescription drugs. The Nevada Attorney General’s Office said more than $13 million from that deal would go into a consumer restitution fund, while impacted Nevada agencies would receive about $41,000.
The Glenmark deal also covered earlier settlements involving Lannett, Bausch, Apotex and Heritage, giving Nevada consumers a clear example of how money from the generic-drug litigation may eventually be distributed. The Sandoz announcement did not yet provide comparable details about Nevada’s allocation or whether individual consumers will be eligible for payments.
What The Sandoz Deal Means For Nevadans
The phrase settlement in principle matters here: the announcement describes a negotiated resolution of allegations, not a final court finding that every claim has been proven. Until the agreement’s final terms and any approval requirements are made public, Nevadans should be wary of unsolicited requests for personal information or payment from anyone claiming to process Sandoz claims.
Sandoz has faced major federal scrutiny before. The Justice Department said in 2021 that Sandoz agreed to pay $185 million to resolve civil allegations tied to generic-drug price fixing and had separately paid a $195 million criminal penalty after admitting to conspiring with other manufacturers.
Nevada’s role in the current fight dates back at least to 2017, when the state joined a coalition accusing generic manufacturers including Sandoz of fixing prices, allocating customers and reducing competition. Monday’s proposed deal gives Ford’s office another chance to turn that long-running case into relief for patients and public programs that depend on affordable medication.
